Detalles de la búsqueda
1.
Intratumoral Administration of a Novel Cytotoxic Formulation with Strong Tissue Dispersive Properties Regresses Tumor Growth and Elicits Systemic Adaptive Immunity in In Vivo Models.
Int J Mol Sci
; 21(12)2020 Jun 24.
Artículo
en Inglés
| MEDLINE | ID: mdl-32599852
2.
Objective response by mRECIST as a predictor and potential surrogate end-point of overall survival in advanced HCC.
J Hepatol
; 66(6): 1166-1172, 2017 06.
Artículo
en Inglés
| MEDLINE | ID: mdl-28131794
3.
Brivanib as adjuvant therapy to transarterial chemoembolization in patients with hepatocellular carcinoma: A randomized phase III trial.
Hepatology
; 60(5): 1697-707, 2014 Nov.
Artículo
en Inglés
| MEDLINE | ID: mdl-24996197
4.
Phase 2 study of CT-322, a targeted biologic inhibitor of VEGFR-2 based on a domain of human fibronectin, in recurrent glioblastoma.
Invest New Drugs
; 33(1): 247-53, 2015 Feb.
Artículo
en Inglés
| MEDLINE | ID: mdl-25388940
5.
Quality of life in patients with K-RAS wild-type colorectal cancer: the CO.20 phase 3 randomized trial.
Cancer
; 120(2): 181-9, 2014 Jan 15.
Artículo
en Inglés
| MEDLINE | ID: mdl-24127364
6.
Selective STING stimulation in dendritic cells primes antitumor T cell responses.
Sci Immunol
; 8(79): eabn6612, 2023 01 13.
Artículo
en Inglés
| MEDLINE | ID: mdl-36638189
7.
Experimental validation of rotating detonation for rocket propulsion.
Sci Rep
; 13(1): 14204, 2023 Aug 30.
Artículo
en Inglés
| MEDLINE | ID: mdl-37648704
8.
Assessing the safety, tolerability and efficacy of PLGA-based immunomodulatory nanoparticles in patients with advanced NY-ESO-1-positive cancers: a first-in-human phase I open-label dose-escalation study protocol.
BMJ Open
; 11(11): e050725, 2021 11 30.
Artículo
en Inglés
| MEDLINE | ID: mdl-34848513
9.
Retreatment with bortezomib alone or in combination for patients with multiple myeloma following an initial response to bortezomib.
Am J Hematol
; 84(10): 657-60, 2009 Oct.
Artículo
en Inglés
| MEDLINE | ID: mdl-19731393
10.
Intratumorally delivered formulation, INT230-6, containing potent anticancer agents induces protective T cell immunity and memory.
Oncoimmunology
; 8(10): e1625687, 2019.
Artículo
en Inglés
| MEDLINE | ID: mdl-31646070
11.
Phase II randomised discontinuation trial of brivanib in patients with advanced solid tumours.
Eur J Cancer
; 120: 132-139, 2019 10.
Artículo
en Inglés
| MEDLINE | ID: mdl-31522033
12.
An observational, retrospective analysis of retreatment with bortezomib for multiple myeloma.
Clin Lymphoma Myeloma
; 8(3): 140-5, 2008 Jun.
Artículo
en Inglés
| MEDLINE | ID: mdl-18650176
13.
Utility of bortezomib retreatment in relapsed or refractory multiple myeloma patients: a multicenter case series.
Clin Adv Hematol Oncol
; 6(10): 755-60, 2008 Oct.
Artículo
en Inglés
| MEDLINE | ID: mdl-18997666
14.
Narrowband (312-nm) UV-B suppresses interferon gamma and interleukin (IL) 12 and increases IL-4 transcripts: differential regulation of cytokines at the single-cell level.
Arch Dermatol
; 139(2): 155-61, 2003 Feb.
Artículo
en Inglés
| MEDLINE | ID: mdl-12588221
15.
Using Modified RECIST and Alpha-Fetoprotein Levels to Assess Treatment Benefit in Hepatocellular Carcinoma.
Liver Cancer
; 3(3-4): 439-50, 2014 Oct.
Artículo
en Inglés
| MEDLINE | ID: mdl-26280005
16.
Brivanib attenuates hepatic fibrosis in vivo and stellate cell activation in vitro by inhibition of FGF, VEGF and PDGF signaling.
PLoS One
; 9(4): e92273, 2014.
Artículo
en Inglés
| MEDLINE | ID: mdl-24710173
17.
The effects of liver impairment on the pharmacokinetics of brivanib, a dual inhibitor of fibroblast growth factor receptor and vascular endothelial growth factor receptor tyrosine kinases.
Cancer Chemother Pharmacol
; 72(1): 53-64, 2013 Jul.
Artículo
en Inglés
| MEDLINE | ID: mdl-23719718
18.
Brivanib in patients with advanced hepatocellular carcinoma who were intolerant to sorafenib or for whom sorafenib failed: results from the randomized phase III BRISK-PS study.
J Clin Oncol
; 31(28): 3509-16, 2013 Oct 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-23980090
19.
Phase III randomized, placebo-controlled study of cetuximab plus brivanib alaninate versus cetuximab plus placebo in patients with metastatic, chemotherapy-refractory, wild-type K-RAS colorectal carcinoma: the NCIC Clinical Trials Group and AGITG CO.20 Trial.
J Clin Oncol
; 31(19): 2477-84, 2013 Jul 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-23690424
20.
Brivanib versus sorafenib as first-line therapy in patients with unresectable, advanced hepatocellular carcinoma: results from the randomized phase III BRISK-FL study.
J Clin Oncol
; 31(28): 3517-24, 2013 Oct 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-23980084